Indivior PLC (LON:INDV – Get Free Report) insider Jo Le Couilliard purchased 1,490 shares of the firm’s stock in a transaction dated Friday, July 26th. The stock was acquired at an average cost of GBX 1,006 ($13.01) per share, with a total value of £14,989.40 ($19,386.19).
Indivior Trading Up 2.7 %
LON INDV opened at GBX 987 ($12.77) on Monday. Indivior PLC has a one year low of GBX 653 ($8.45) and a one year high of GBX 1,927 ($24.92). The company has a 50-day simple moving average of GBX 1,172.64 and a 200-day simple moving average of GBX 1,387.37. The company has a debt-to-equity ratio of 2,790.00, a quick ratio of 1.52 and a current ratio of 0.93. The firm has a market capitalization of £1.33 billion, a PE ratio of 32,900.00, a price-to-earnings-growth ratio of -5.57 and a beta of 0.06.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft decreased their price target on shares of Indivior from GBX 2,350 ($30.39) to GBX 1,500 ($19.40) and set a “buy” rating for the company in a report on Tuesday, July 9th.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
- Five stocks we like better than Indivior
- ESG Stocks, What Investors Should Know
- Is Crypto Cool Again? What Stocks You Should Be Watching
- 3 Small Caps With Big Return Potential
- Why Call Options Volume for These 2 Stocks Spiked Together
- What is the Euro STOXX 50 Index?
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.